Introduction Information obtained on the IL-2 receptor status of tumour infiltrating lymphocytes in patients suffering from squamous cell carcinoma of the head and neck (SSCHN) before and after IL-2 treatment may lead to a better understanding of the immunological changes and related kinetics induced at the tumour level and ultimately to a strategy that allows selection of those patients that will benefit from IL-2 therapy. This study set out to assess the relationship between 123 I-IL2 single-photon emission computed tomography (SPECT) findings and the presence of IL-2 receptors (CD25 staining) on tumour-infiltrating lymphocytes as well as on SCCHN tumour cells in patients suffering from SCCHN. Materials and methods Seventeen consecutive patients (12 men; mean age, 57 years) highly suspected to suffer from SSCHN were prospectively included in the study. All patients underwent planar and whole body 123 I-IL2 scintigraphy and underwent surgery or had a biopsy taken within 1 week from imaging. Surgical resected primary lesions as well as biopsy material from primary tumours were histologically analysed with respect to the presence and intensity of CD25 expression on tumour infiltrating lymphocytes and tumour cells (HSCORE). Tumor-to-background (T/N) ratios of the primary tumour derived from planar and tomographic 123 I-IL2 scintigraphy were related to the results derived from histology. Results All patients suffered from SSCHN. T/N ratios derived from SPECT images were significantly correlated with CD25 lymphocyte HSCOREs (r=0.66; p=0.03), but not with CD25 tumour cell HSCOREs. Conclusions 123 I-IL-2 SPECT imaging allows for noninvasive imaging of the relative amount of IL-2 receptors present on tumour infiltrating lymphocytes in SCCHN.
Introduction
The immunology of patients suffering from squamous cell carcinoma of the head and neck (SCCHN) has been a subject of great interest for many years. Immunosuppression seems to be more frequent and more profound in these patients than in patients with malignancies involving other sites [1, 2] . Several clinical trials have addressed the effect of high-dose systemic treatment with the immunomodulating cytokine interleukin-2 (IL-2) in this patient population to overcome immunosuppression [3, 4] . In SCCHN patients, poor treatment response rates of, on average, 20-30% were reported for Il-2 therapy. In addition to a high toxicity profile, systemic high-dose administration mainly stimulates non-specific lymphokine-activated killer activity through low-affinity IL-2 receptors and does not lead to systemic immunity. As opposed to high-dose IL-2 systemic treatment, local application of low-dose IL-2 in experimental cancer models as well as in SCCHN patients proved more effective, and this without toxic side effects [5, 6] . In experimental models, local administration of low-dose IL-2 only proved effective when given relatively late after inoculation of tumour cells, suggesting the requirement of an already ongoing but probably weak T-cell-driven anti-tumour reaction that is boosted by the locally administered IL-2 [7] . In the clinical setting, the mechanisms involved and the kinetics of T cell expansion are poorly documented, likely reflecting the difficulty in obtaining sequential biopsy material at appropriate times after therapy. In addition, the appropriate timing for serial biopsies, even if they were feasible, is currently unclear.
IL-2 exerts its effect through binding to high-affinity trimeric receptors made up of an alpha-chain (CD25), a beta-chain and a gamma-chain [8] . Radiolabelled 123 I-IL2 was shown previously to specifically bind to functional IL-2 receptors and to allow for specific visualisation of functional IL-2 receptors expressed on activated T lymphocytes [9, 10] . Accordingly, this study set out to assess the relationship between 123 I-IL2 single-photon emission computed tomography (SPECT) findings and the presence of IL-2 receptors (CD25 staining) on tumour-infiltrating lymphocytes as well as on SCCHN tumour cells in patients suffering from SCCHN.
Materials and methods

Patients
This study was approved by the Ethics Committee of the Ghent University Hospital and performed according to good clinical practice. Seventeen consecutively collected patients (12 men and 5 women; age range, 44-79 years) highly suspected to suffer from primary squamous cell carcinoma of the head and neck scheduled to undergo surgical resection or a biopsy were prospectively included in the study. All patients gave their written informed consent before inclusion. None of the patients suffered from clinically significant hepatic or renal disease or other conditions likely to interfere with the distribution, metabolism or excretion of 123 IL-2. All patients underwent whole body and tomographic 123 I-IL2 scintigraphy and underwent surgery or had a biopsy taken within 1 week from imaging. Surgical resected primary tumour lesions or biopsy material of the primary tumour were histologically analysed with respect to the presence of CD25 expression on tumour infiltrating lymphocytes and tumour cells. Tumor-to-background ratios derived from whole body and tomographic 123 I-IL2 scintigraphy were related to the results derived from histology. The American Joint Committee on Cancer version 6 TNM criteria were used for stage delineation. Baseline staging incorporated all physical findings, diagnostic imaging and available pathology results.
I-IL2 preparation
Human recombinant Il-2 (Cetus, The Netherlands) was labelled using an enzymatic method described previously [10] . Unbound iodine and unlabelled IL-2 were removed by high-performance liquid chromatography (HPLC) on a Gilson system using a reverse-phase column (Dynamax A300, 5 μm, 4.6×250 mm, Rainin, USA). HPLC-purified 123 I-IL-2 was purged for 20 min at 30°C with N2 to remove acetonitrile and trifluoracetic acid, diluted to 5 ml with 5% glucose and sterilised by filtration through a 0.22-μm lowprotein binding filter. Biological activity of 123 I-IL2 was assessed as described previously [10] .
I-IL-2 scintigraphy
All patients were pretreated with 300 mg potassium iodide orally to block thyroid uptake of free radioactive iodide. Whole body images, planar spot images and tomographic images were performed between 1 and 2 h post-injection of 64-111 MBq 123 I-IL-2 using a triple-headed gamma camera (Irix, Picker, USA) equipped with low-energy highresolution collimators. The peak energy used was 159 keV, with a 15% window. The useful peak energy of the collimators used is 160 keV with a septal penetration of 1.5%. SPECT images were acquired over 15 min by 40 views of 20 s per detector (60 angles; 3°angle; matrix size, 128×128). Transversal, coronal and sagittal slices were reconstructed iteratively using ordered subset expectation maximization (six subsets and four iterations) and post-filtered using a Butterworth filter (cutoff frequency 0.8, order 7).
Data analysis
Histology
Five-millimeter sections were freed of paraffin, and endogenous peroxidase activity was blocked with H 2 O 2 . A primary antibody targeting human CD25 (1:200 dilution; neoMarkers) was incubated for 1 h at room temperature followed by a secondary antibody incubation (biotinylated goat anti-mouse, 1:40 dilution) for 30 min at room temperature. Then, avidin biotin amplification (ABC kit; Dakocytomation) was added for 30 min. Incubation with AEC (3-amino-9-ethylcarbazole) chromogen kit (Sigma) at room temperature for 5-10 min produced a red reaction pigment. CD25-positive tumour cells and lymphocytes were counted separately at a magnification of 400× using a test grid with a 0.22-mm 2 area. Intensities of staining were classified from 0 (absent staining) to 4 (high staining). A score of 1,2 or 3 corresponds, respectively, with very low, low and intermediate intensity of staining. For each malignancy, a value designated as HSCORE was obtained by an experienced histologist, blinded to the clinical and scintigraphic findings, after the application of the following algorithm for both tumour cells and lymphocytes:
Þxn where I and n represent the number of cells that stained at each intensity, respectively. Double staining for CD3 and CD25 was performed to confirm that T lymphocytes were CD25-positive as described previously (data not shown). Sections were first incubated with monoclonal antibodies to CD25; the reaction was revealed incubating the sections with a streptavidinfluorescein conjugate (fluorescein isothiocyanate). After the first reaction, a second reaction with primary antibodies to CD3 was induced, and fluorescence was obtained with a streptavidin-Texas red fluorescent conjugate. Control sections were incubated with a mixture of irrelevant monoclonal reagents with a similar isotype. Images were acquired by means of the Noran confocal microscope; three-dimensional stacks were acquired at a resolution of 0.1 μm in the x, y and z axes.
I-IL-2 scintigraphy
All studies were reviewed by two experienced observers, familiar with the normal biodistribution of 123 I-IL-2 in patients, blinded to the histological findings. Images were reviewed for the presence or absence of focally increased uptake at the site of the primary tumour lesion known from clinical findings and/or other imaging modalities. Tumour to background ratios were determined by drawing an irregular region of interest around the primary tumour on the transaxial tomographic slice including the maximal tumour diameter guided by CT fusion (commercially available software, HERMES, Nuclear Diagnostics, Sweden); an identical sized region of interest in adjacent normal tissue was then determined, and a tumour to normal tissue ratio (T/N) determined.
Statistical analysis
Differences in HSCORES between different disease stages were assessed using an unpaired two-tailed Wilcoxon test. A possible correlation between T/N ratios and HSCORES was assessed using the Spearman rank correlation test. The significance level used was ≤0.05. Bonferroni correction was applied to correct for multiple comparisons. SPPS version 12.0 was used for statistical analysis. Intra-and inter-observer reproducibility was assessed by intra-class correlation analysis. Sample size was determined a priori by power analysis anticipating an α error of 0.05 (two-sided), a power of 0.8 and a correlation coefficient of 0.6 (the latter based on available data in melanoma patients using 99m Tc-IL-2). The calculated required sample size (n=13) was a 
Results
Patient data are shown in Table 1 . All patients suffered from SSCHN. Five patients presented with stage III disease; 12 patients presented with stage IV disease.
In three patients, tumour material available for histological examination proved too small or non-representative.
In 10 out of 14 evaluable patients, CD25-positive lymphocytes were identified. Median CD25+ lymphocyte HSCORE for the group of 14 patients was 20 (range, 0-80).
CD25-positive lymphocyte HSCORES were not significantly different in patients suffering from stage III disease when compared to patients suffering from stage IV disease.
In 9 out of 14 evaluable patients, CD25-positive tumour cells were identified. Median CD25-positive tumour cell HSCORE for the group of 14 patients was 10 (range, 0-60). CD25-positive tumour cell HSCOREs were not significantly different in patients suffering from stage III disease when compared to patients suffering from stage IV disease.
Intra-class correlation coefficients for HSCORE analysis were, respectively, r=0.945 (p=0.0001) and r=0.87 (p= 0.0001) for intra-and inter-observer analysis.
In patients that underwent IL-2 scintigraphy, only three tumours displayed straightforward uptake on planar imaging. In contrast, in 14 out of 17 patients included, tumours were IL-2-positive on tomography. The median T/N ratio derived from SPECT imaging was 1.2 (range, 1-2.7). Intraclass correlation coefficients for T/N ratio analysis were, respectively, r=0.95 (p=0.0001) and r=0.89 (p=0.0001) for intra-and inter-observer analysis.
T/N ratios derived from SPECT images were significantly correlated with the corresponding CD25 lymphocyte HSCOREs (Spearman correlation coefficient r=0.66; p= 0.03 after Bonferroni correction), but not with CD25 tumour cell HSCORES (see Figs. 1, 2 and 3) .
Discussion
In the series presented, uptake of 123 I-IL2 was found in approximately 80% of SCCHN. This uptake was significantly correlated to the presence and density of CD25 (HSCORE), but not with CD25+ tumour cell HSCORES.
Tumour infiltrating lymphocytes (TILs) are known to be equipped with fully functional high-affinity (αβγ complex) IL-2 receptors [11] . In SCCHN, Boscia et al. [12] found that IL-2R was mainly expressed by activated TILs along with different surface antigens. These TILs showed when cultured in media containing natural IL-2, sustained growth and anti-tumour effector function. Similarly, Boheim K. et al. [13] documented in 13 out of 22 frozen section biopsies of patients suffering from SCCHN the expression of CD25 on TILs. In their series, larger amounts of CD25-positive TILs were observed in stage III than in stage IV tumours. Similar to the findings by Boheim et al., in our series, CD25-positive TILs were present in 10 out of 14 evaluable tumour; however, HSCOREs did not differ significantly in patients suffering from stage III disease vs stage IV disease. The latter finding may relate to the small number of patients studied. In line with results obtained previously by Signore et al. [14] using 99m Tc-labelled IL-2 for the imaging of melanoma lesions, tumour-to-background ratios obtained in our series using [15] [16] [17] . On the other hand Cortesina et al. [18] doses of 8-500 U/ml of IL2 were able to inhibit growth of 11 of 16 SCCHN lines tested [12] . In addition, in an immunosuppressed SCCHN xenografted nude mouse model, both locally and systemically administered rIL-2 significantly inhibited growth of SCCHN. The absence of a significant inflammatory infiltrate in or around the xenografts in this model, related to the immunosuppression, argued strongly for a direct effect of IL2 on tumour cells rather than for an effector host macrophage-mediated effect [19] . Contrary to the findings by Weidmann, in the series presented, 9 out of 14 histologically evaluable tumours expressed CD25. While statistical analysis suggested the existence of a relationship between CD25 expressed on tumour cells and 123 I-IL2 T/N ratios, scatterplot analysis, however, showed that the suggested statistical relationship was solely determined by an outlier value. The lack of a relationship between 123 I-IL2 T/N ratios and CD25+ tumour cell HSCOREs found in this study with relatively higher CD25 HSCORE values for tumour cells when compared to lymphocytes in 6 out of 14 evaluable patients suggests that contrary to the findings by Cortesina et al. in cell lines, IL-2Rs expressed on human SCCHN are not functional, and thus, unable to internalise IL-2. This finding is essential for the potential clinical relevance of 123 IL-2 imaging in SCCHN patients, given, in clinical practice, it will be impossible to differentiate in a primary tumour uptake in tumour cells from lymphocytes and response to IL-2 therapy is mainly related to uptake in lymphocytes.
Theoretically, locally produced Il-2 may interfere with uptake of 123 I-IL2. However, in SCCHN, Knerer et al. [20] , looking at cytokine expression by means of real-time polymerase chain reaction in tumour specimens and adjacent mucosa from 12 SCCHN patients, found no expression of IL-2. While Reichert et al. [21] , using immunohistochemistry, found that all 34 SCCHN samples stained positive for IL-2, staining was confined to the cytoplasm of the tumour cells. Accordingly, based on currently available data, no competitive interference by naturally endogenously produced IL-2 is to be expected in keeping with the good correlation obtained.
Patients suffering from SCCHN have high levels of serum soluble CD25 in their blood [22, 23] . The mechanisms of release of CD25 are likely to be complex. Release of CD25 parallels activation of T cells and in vitro activated human T cells release CD25 in culture supernatants [24] . It has also been shown that supernatant of SCCHN cell lines can stimulate natural killer cells to up-regulate cell surface expression of CD25 and to release soluble CD25 [25] . On the other hand, the lack of extensive CD25 expression on human SCCHN might also be due to cleavage from the tumour cells. Irrespective of its origin, high serum soluble CD25 levels may prevent IL-2, and thus also 123 I-IL-2, from binding to IL-2 receptors expressed on the surface of cells. However, CD25 has a low affinity (Kd=10 nM) for IL-2. Additionally, while IL-2 has a very rapid association rate with CD25, approximately 100-fold faster than IL-2 binding to CD70, the dissociation rate from CD25 is also very fast [26] . Furthermore, in previous studies with 123 I-IL-2 in patients with Coeliac disease or Crohn's diseases in which soluble CD25 levels were measured, a role of these sCD25s to bind 123 IL-2 has always been ruled out [10, 27] . Finally, high persisting blood pool activity at the timing of imaging would have been emerged, which was not the case in either of the patients studied.
To conclude, this pilot study presented suggests that 123 I-IL-2 SPECT imaging may be useful to visualise sequentially and non-invasively the relative amount of IL-2 receptors present on TILs in SCCHN. Information obtained through 123 I-IL-2 imaging may eventually lead to a better understanding of immunological changes induced at the tumour level and to a strategy that allows selection of those patients that will benefit from IL-2 therapy, thus, avoiding significant and unnecessary toxicity. Additional studies in larger patient populations are required.
